Form 4: Protagonist Therapeutics Chief Medical Officer Sells Shares to Cover Tax Obligations

Protagonist Therapeutics' Chief Medical Officer, Arturo Molina, sold 1,906 shares of common stock to cover tax obligations related to the settlement of restricted stock units.

Summary

• Arturo Molina, the Chief Medical Officer of Protagonist Therapeutics, sold 1,906 shares of the company's common stock on November 15, 2024.
• The sale was executed at a price of $40.98 per share.
• This transaction was conducted to cover tax withholding obligations arising from the settlement of restricted stock units.
• Following the sale, Mr. Molina directly owns 46,444 shares of Protagonist Therapeutics common stock.

Sentiment

Score: 5

Explanation: This is a neutral event, a routine transaction for tax purposes, and does not indicate any positive or negative sentiment about the company's performance.

Industry Context

This is a routine transaction for company executives who receive stock-based compensation. It is common for executives to sell shares to cover tax liabilities when restricted stock units vest.

Comparison to Industry Standards

• Sales of shares by executives to cover tax obligations are a common practice across the biotechnology industry.
• Many companies use restricted stock units as part of their compensation packages, leading to similar transactions by executives at other firms.
• The number of shares sold and the price are specific to this individual and company, but the underlying reason for the sale is typical.

Stakeholder Impact

• The sale of shares by an executive may have a minor impact on the stock price, but it is generally not considered a significant event.

Key Dates

Keywords

Protagonist Therapeutics, PTGX, insider trading, stock sale, Form 4, Arturo Molina, Chief Medical Officer, restricted stock units, tax obligations